Editorial: Regulators must step up stem cell oversight (subscription)

A growing number of clinics are offering cell therapies that remain untested in rigorous clinical trials. Although the scientific community has chided the use of unproven treatments, we need less talk and more action in regulating stem cell therapies. (Click here to continue reading)

Leave a Reply

Your email address will not be published. Required fields are marked *